BRISTOL-MYERS Squibb today announced that patients with recurrent or metastatic squamous cell carcinoma of the head and neck will have access to Opdivo (nivolumab) via the Pharmaceutical Benefits Scheme (PBS) from 01 Aug.
The monotherapy authority required streamlined PBS listing represents the first time patients with recurrent or metastatic head and neck cancer will have PBS reimbursed access to an immuno-oncology therapy.
This will provide healthcare professionals and patients with a new and affordable treatment option for this hard-to-treat cancer that often requires a multifaceted approach of surgery, radiotherapy, chemotherapy and supportive care, BMS said.
Approved PI is at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 18
